The Food and Drug Administration today released draft guidance for assessing risk evaluation and mitigation strategies. FDA may require a REMS before approving certain drugs, including biologics, to help ensure its benefits outweigh its risks. FDA Commissioner Scott Gottlieb, M.D., said the guidance provides a framework for companies to develop an assessment plan when they develop a REMS program to improve the quality of the information used to assess the program’s effectiveness and provide post-market evidence that the REMS is meeting its risk mitigation goals. “We need to make sure that the REMS are achieving their public health goals, and that we’re designing and implementing these approaches in ways that minimize burdens to patients and providers,” he said.

Related News Articles

Headline
The Food and Drug Administration today proposed reclassifying surgical staplers for internal use as moderate-risk rather than low-risk medical devices.
Headline
Civica Rx, the not-for-profit generic drug company, officially opened its headquarters last week in Lehi, Utah.
Blog
We must address the racial, ethnic and socioeconomic disparities that increase the risk of negative perinatal outcomes for women of color.
Blog
AHA Executive Vice President Maryjane Wurth previews AHA’s Team Training Conference, where different interdisciplinary groups from diverse health care settings…
Headline
The Food and Drug Administration today ordered manufacturers to immediately stop selling and distributing surgical mesh products for transvaginal repair of…
Headline
Readmissions penalties for hospitals with the greatest share of dually eligible beneficiaries could fall by an estimated $22.4 million in fiscal year 2019,…